JP2020529593A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020529593A5 JP2020529593A5 JP2020504364A JP2020504364A JP2020529593A5 JP 2020529593 A5 JP2020529593 A5 JP 2020529593A5 JP 2020504364 A JP2020504364 A JP 2020504364A JP 2020504364 A JP2020504364 A JP 2020504364A JP 2020529593 A5 JP2020529593 A5 JP 2020529593A5
- Authority
- JP
- Japan
- Prior art keywords
- factor
- blood sample
- coagulation
- clot formation
- series
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000015081 Blood Coagulation Factors Human genes 0.000 claims description 71
- 108010039209 Blood Coagulation Factors Proteins 0.000 claims description 71
- 239000003114 blood coagulation factor Substances 0.000 claims description 71
- 230000035602 clotting Effects 0.000 claims description 54
- 230000015271 coagulation Effects 0.000 claims description 33
- 238000005345 coagulation Methods 0.000 claims description 33
- 230000005764 inhibitory process Effects 0.000 claims description 21
- 230000001419 dependent effect Effects 0.000 claims description 11
- 239000003112 inhibitor Substances 0.000 claims description 8
- 238000011144 upstream manufacturing Methods 0.000 claims description 5
- 239000008280 blood Substances 0.000 claims 95
- 210000004369 blood Anatomy 0.000 claims 95
- 238000000034 method Methods 0.000 claims 39
- 108010074860 Factor Xa Proteins 0.000 claims 25
- 108010029144 Factor IIa Proteins 0.000 claims 18
- 230000007812 deficiency Effects 0.000 claims 17
- 230000037361 pathway Effects 0.000 claims 12
- 238000001514 detection method Methods 0.000 claims 9
- 108010000487 High-Molecular-Weight Kininogen Proteins 0.000 claims 6
- 102100035792 Kininogen-1 Human genes 0.000 claims 6
- 239000011324 bead Substances 0.000 claims 6
- 102000013566 Plasminogen Human genes 0.000 claims 4
- 108010051456 Plasminogen Proteins 0.000 claims 4
- 102000004179 Plasminogen Activator Inhibitor 2 Human genes 0.000 claims 4
- 108090000614 Plasminogen Activator Inhibitor 2 Proteins 0.000 claims 4
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 claims 4
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 claims 4
- 102100030951 Tissue factor pathway inhibitor Human genes 0.000 claims 4
- 230000015572 biosynthetic process Effects 0.000 claims 4
- 108010013555 lipoprotein-associated coagulation inhibitor Proteins 0.000 claims 4
- 229960000187 tissue plasminogen activator Drugs 0.000 claims 4
- 102000008946 Fibrinogen Human genes 0.000 claims 3
- 108010049003 Fibrinogen Proteins 0.000 claims 3
- 238000004566 IR spectroscopy Methods 0.000 claims 3
- 208000007536 Thrombosis Diseases 0.000 claims 3
- 239000003146 anticoagulant agent Substances 0.000 claims 3
- 229940127219 anticoagulant drug Drugs 0.000 claims 3
- 230000006624 extrinsic pathway Effects 0.000 claims 3
- 229940012952 fibrinogen Drugs 0.000 claims 3
- 238000000684 flow cytometry Methods 0.000 claims 3
- 238000001917 fluorescence detection Methods 0.000 claims 3
- 230000006623 intrinsic pathway Effects 0.000 claims 3
- 230000031700 light absorption Effects 0.000 claims 3
- 239000003550 marker Substances 0.000 claims 3
- 108010025221 plasma protein Z Proteins 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 238000011002 quantification Methods 0.000 claims 3
- 239000000758 substrate Substances 0.000 claims 3
- 230000000007 visual effect Effects 0.000 claims 3
- 108090000935 Antithrombin III Proteins 0.000 claims 2
- 102000004411 Antithrombin III Human genes 0.000 claims 2
- 102100037362 Fibronectin Human genes 0.000 claims 2
- 108010067306 Fibronectins Proteins 0.000 claims 2
- 108090000481 Heparin Cofactor II Proteins 0.000 claims 2
- 102100030500 Heparin cofactor 2 Human genes 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 108090000113 Plasma Kallikrein Proteins 0.000 claims 2
- 102100034869 Plasma kallikrein Human genes 0.000 claims 2
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 claims 2
- 101800004937 Protein C Proteins 0.000 claims 2
- 102000017975 Protein C Human genes 0.000 claims 2
- 229940096437 Protein S Drugs 0.000 claims 2
- 108010066124 Protein S Proteins 0.000 claims 2
- 102000029301 Protein S Human genes 0.000 claims 2
- 101800001700 Saposin-D Proteins 0.000 claims 2
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 claims 2
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 claims 2
- 102000003801 alpha-2-Antiplasmin Human genes 0.000 claims 2
- 108090000183 alpha-2-Antiplasmin Proteins 0.000 claims 2
- 229960005348 antithrombin iii Drugs 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims 2
- 229960000856 protein c Drugs 0.000 claims 2
- 238000007711 solidification Methods 0.000 claims 2
- 230000008023 solidification Effects 0.000 claims 2
- 239000000725 suspension Substances 0.000 claims 2
- 229960005356 urokinase Drugs 0.000 claims 2
- 108010079356 FIIa Proteins 0.000 claims 1
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 claims 1
- 102100039418 Plasminogen activator inhibitor 1 Human genes 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000003292 diminished effect Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 229940012444 factor xiii Drugs 0.000 claims 1
- 239000012530 fluid Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 239000003130 blood coagulation factor inhibitor Substances 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762538618P | 2017-07-28 | 2017-07-28 | |
| US62/538,618 | 2017-07-28 | ||
| US201862699665P | 2018-07-17 | 2018-07-17 | |
| US62/699,665 | 2018-07-17 | ||
| PCT/US2018/043973 WO2019023508A1 (en) | 2017-07-28 | 2018-07-26 | METHODS AND DEVICES FOR DETECTION OF ANTICOAGULANTS IN PLASMA AND WHOLE BLOOD |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020529593A JP2020529593A (ja) | 2020-10-08 |
| JP2020529593A5 true JP2020529593A5 (enExample) | 2021-08-26 |
| JP7214712B2 JP7214712B2 (ja) | 2023-01-30 |
Family
ID=63405342
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020504364A Active JP7214712B2 (ja) | 2017-07-28 | 2018-07-26 | 血漿および全血中の抗凝固薬の検出のための方法ならびにデバイス |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US20190111431A1 (enExample) |
| EP (1) | EP3658920A1 (enExample) |
| JP (1) | JP7214712B2 (enExample) |
| KR (1) | KR20200034749A (enExample) |
| CN (1) | CN111094990A (enExample) |
| AU (1) | AU2018307799A1 (enExample) |
| CA (1) | CA3071295A1 (enExample) |
| IL (1) | IL272320A (enExample) |
| SG (1) | SG11202000688UA (enExample) |
| WO (1) | WO2019023508A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2750839C1 (ru) * | 2020-05-18 | 2021-07-05 | Общество с ограниченной ответственностью "Меднорд-Техника" (ООО "Меднорд-Т") | Устройство и способ экспресс-оценки агрегационной активности форменных элементов крови |
| US20220283190A1 (en) * | 2021-03-08 | 2022-09-08 | Galit H. Frydman | Methods and devices for detection of coagulation impairment |
| CN113945551A (zh) * | 2021-10-19 | 2022-01-18 | 重庆医科大学附属永川医院 | 一种血小板功能的微流控分析检测模型 |
| CN114558629B (zh) * | 2022-03-03 | 2024-06-04 | 四川微康朴澜医疗科技有限责任公司 | 一种微流控式血栓弹力分析检测试剂盒 |
| IL319816A (en) | 2022-09-30 | 2025-05-01 | Coagulo Medical Tech Inc | Modular microfluidic cartridge testing device, useful for point-of-care medical diagnostics and other applications |
| WO2025132678A1 (en) * | 2023-12-19 | 2025-06-26 | F. Hoffmann-La Roche Ag | Qualitative test for direct oral anticoagulants (doacs) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2040073A1 (en) | 2007-09-20 | 2009-03-25 | Iline Microsystems, S.L. | Microfluidic device and method for fluid clotting time determination |
| WO2013067536A1 (en) | 2011-11-04 | 2013-05-10 | Massachusetts Institute Of Technology | Multi-parameter thrombotic assay apparatus, systems, and methods |
| US9709579B2 (en) | 2012-06-27 | 2017-07-18 | Colorado School Of Mines | Microfluidic flow assay and methods of use |
| US20140038204A1 (en) | 2012-07-31 | 2014-02-06 | Baxter Healthcare S.A. | Selective measurement of active human protease coagulation factors |
| US9562914B2 (en) * | 2013-10-16 | 2017-02-07 | President And Fellows Of Harvard College | Microfluidic device for real-time clinical monitoring and quantitative assessment of whole blood coagulation |
| EP3191836B1 (en) | 2014-09-09 | 2022-11-23 | Perosphere Technologies Inc. | Microfluid chip-based, universal coagulation assay |
-
2018
- 2018-07-26 CN CN201880059719.9A patent/CN111094990A/zh active Pending
- 2018-07-26 JP JP2020504364A patent/JP7214712B2/ja active Active
- 2018-07-26 EP EP18760075.4A patent/EP3658920A1/en not_active Withdrawn
- 2018-07-26 CA CA3071295A patent/CA3071295A1/en active Pending
- 2018-07-26 WO PCT/US2018/043973 patent/WO2019023508A1/en not_active Ceased
- 2018-07-26 US US16/046,816 patent/US20190111431A1/en not_active Abandoned
- 2018-07-26 SG SG11202000688UA patent/SG11202000688UA/en unknown
- 2018-07-26 KR KR1020207004767A patent/KR20200034749A/ko not_active Abandoned
- 2018-07-26 AU AU2018307799A patent/AU2018307799A1/en not_active Abandoned
-
2020
- 2020-01-28 IL IL272320A patent/IL272320A/en unknown
-
2023
- 2023-01-25 US US18/159,281 patent/US20230166255A1/en not_active Abandoned
- 2023-01-25 US US18/159,276 patent/US20230158498A1/en not_active Abandoned
- 2023-01-25 US US18/159,283 patent/US20230158499A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020529593A5 (enExample) | ||
| Levi | Pathogenesis and diagnosis of disseminated intravascular coagulation | |
| Gando et al. | Disseminated intravascular coagulation | |
| Levi et al. | How I treat disseminated intravascular coagulation | |
| Mackie et al. | Guidelines on the laboratory aspects of assays used in haemostasis and thrombosis. | |
| Lippi et al. | Biochemical markers for the diagnosis of venous thromboembolism: the past, present and future | |
| Miszta et al. | A high-fat diet delays plasmin generation in a thrombomodulin-dependent manner in mice | |
| Gando | Disseminated intravascular coagulation in trauma patients | |
| Hans et al. | The place of viscoelastic testing in clinical practice | |
| Müller et al. | Utility of thromboelastography and/or thromboelastometry in adults with sepsis: a systematic review | |
| Levi et al. | DIC: which laboratory tests are most useful | |
| Wuillemin et al. | Activation of the intrinsic pathway of coagulation in children with meningococcal septic shock | |
| JP4505045B2 (ja) | 血液凝固時間の延長原因の判定法 | |
| Caires et al. | Identification of a 14 kDa endocan fragment generated by cathepsin G, a novel circulating biomarker in patients with sepsis | |
| Sayyadi et al. | Status of major hemostatic components in the setting of COVID-19: the effect on endothelium, platelets, coagulation factors, fibrinolytic system, and complement | |
| Cugno et al. | Increase of bradykinin in plasma of patients undergoing cardiopulmonary bypass: the importance of lung exclusion | |
| JP7214712B2 (ja) | 血漿および全血中の抗凝固薬の検出のための方法ならびにデバイス | |
| Wan et al. | Added value of blood cells in thrombin generation testing | |
| Maier et al. | COVID-19 patient plasma demonstrates resistance to tPA-induced fibrinolysis as measured by thromboelastography | |
| Levi et al. | Coagulation biomarkers in critically ill patients | |
| Gosselin et al. | Measuring direct oral anticoagulants | |
| US7923255B2 (en) | Method of detecting platelet thrombosis or organ failure | |
| Scarlatescu et al. | Validation of the time to attain maximal clot amplitude after reaching maximal clot formation velocity parameter as a measure of fibrinolysis using rotational thromboelastometry and its application in the assessment of fibrinolytic resistance in septic patients: a prospective observational study: communication from the ISTH SSC Subcommittee on Fibrinolysis | |
| Hanekom et al. | The active fraction of plasmatic plasminogen activator inhibitor type 1 as a possible indicator of increased risk for metastatic melanoma | |
| Kamada et al. | In vitro evaluation of blood coagulation activation and microthrombus formation by a microchannel array flow analyzer |